R
Reneo Pharmaceuticals
Biotech & Life Sciences · Irvine, United States · Founded 2017 · IPO 2021
Focused on the development of therapies for patients with genetically defined orphan diseases MoreLess
Reneo Pharmaceuticals is a clinical-stage pharmaceutical company dedicated to developing therapies for rare genetic metabolic disorders. The company primarily focuses on conditions such as McArdle disease and primary mitochondrial myopathies (PMMs), which are characterized by severe muscle pain, weakness, and activity intolerance due to genetic mutations affecting muscle glycogen and mitochondrial function. Reneo's lead investigational compound, REN001, aims to enhance cellular energy metabolism by regulating genes involved in mitochondrial activity.
Reneo serves patients suffering from these rare diseases, operating in the biopharmaceutical market. The company's business model revolves around the research, development, and eventual commercialization of its therapeutic compounds. Revenue generation is anticipated through the successful approval and sale of these therapies, as well as potential partnerships and licensing agreements with larger pharmaceutical firms.
Keywords: rare diseases, genetic disorders, metabolic disorders, McArdle disease, mitochondrial myopathies, REN001, cellular energy, biopharmaceutical, clinical-stage, therapeutic development.
Company overview
Reneo Pharmaceuticals company information
The essential company record, classifications and operating signals in one place.
- Status
- Acquired
- Founded
- 2017
- Headquarters
- Irvine, United States
- Employees
- 13
- Open positions
- None listed
- Dealroom signal
- 32.2
Valuation & funding
Reneo Pharmaceuticals funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| ACQUISITIONOther financing | May 2024 | $0 | — | OnKure | ↗ |
| POST IPO EQUITYOther financing | May 2024 | $65M | — | Samsara BioCapital · Surveyor Capital · Vestal Point Capital · Cormorant Asset Management | ↗ |
| POST IPO EQUITYOther financing | May 2023 | $55M | — | Undisclosed | ↗ |
| POST IPO SECONDARYOther financing | May 2022 | $20M | — | Undisclosed | ↗ |
| IPOOther financing | Apr 2021 | $94M | $94M | Undisclosed | — |
| SERIES BOther financing | Dec 2020 | Novo Ventures · NEA · Aisling Capital · Pappas Capital | — | ||
| SERIES AOther financing | May 2019 | Lundbeckfonden Ventures · Pappas Capital · NEA | ↗ |
Financials
Revenue, earnings and profit over time
Reported history and available estimates. Estimated years are marked “E”; sparse fields are left blank rather than inferred.
| Year | Revenue | Growth | EBITDA | Margin |
|---|---|---|---|---|
| 2026 | $375K | — | −$83M | -22102.1% |
| 2025 | $0 | — | −$83M | — |
| 2024 | $0 | — | −$83M | — |
| 2023 | $0 | — | −$83M | — |
| 2022 | $0 | — | −$54M | — |
| 2021 | $0 | — | −$40M | — |
| 2020 | $0 | — | −$20M | — |
Growth signals
Reneo Pharmaceuticals website traffic
Latest recorded traffic for Reneo Pharmaceuticals is 8.5K monthly website visits, up 12042.9% over the last three months. Reneo Pharmaceuticals's team declined 53.6% over the past year.
Comparisons
Reneo Pharmaceuticals compared with similar companies
Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.
Talent graph
Reneo Pharmaceuticals's talent
Source: Dealroom Talent Intelligence.
Global footprint
Where Reneo Pharmaceuticals has talent and traffic
In the news
Latest news about Reneo Pharmaceuticals
Recent press, funding announcements, and product moves mentioning Reneo Pharmaceuticals — open to read from the original sources.
Market sentiment
What the market is saying about Reneo Pharmaceuticals
An AI-synthesized read of the highest-engagement posts about Reneo Pharmaceuticals on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Reneo Pharmaceuticals’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.